

CITATION REPORT

List of articles citing

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/az

DOI: 10.1016/j.hrthm.2020.05.014
Heart Rhythm, 2020, 17, 1425-1433.

Source: <https://exaly.com/paper-pdf/76635376/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
216	Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. 2020 , 13, e008937		9
215	Malignant Arrhythmias in Patients With COVID-19: Incidence, Mechanisms, and Outcomes. 2020 , 13, e008920	32	
214	Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers. 2020 , 22, 30		0
213	[COVID-19 and arrhythmias]. 2020 , 69, 376-379		
212	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519		16
211	Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19. 2020 , 43, 1624-1630		18
210	Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. 2020 , 117, 27381-27387		101
209	The Clinical Utility of Continuous QT Interval Monitoring in Patients Admitted With COVID-19 Compared With Standard of Care: A Prospective Cohort Study. 2020 , 2, 592-598		
208	Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients. 2020 , 38, 101881		3
207	QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. 2020 , 30, 1482-1485		5
206	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190		44
205	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. 2020 , 9,		23
204	Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. 2020 , 11, 587709		6
203	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,		2
202	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441		2
201	A systematic review of ECG findings in patients with COVID-19. 2020 , 72, 500-507		26
200	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. 2020 , 7, 581521		23

199	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). 2020 , 4, 121-131	
198	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. 2020 , 56, 106212	9
197	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
196	Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. 2020 , 11, 874-894	41
195	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
194	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. 2020 , 13, e009007	6
193	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
192	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. 2020 , 15, 350-358	17
191	Cardiac arrhythmias in patients with COVID-19. 2020 , 36, 827-836	44
190	Azithromycin/hydroxychloroquine. 2020 , 1822, 69-69	
189	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. 2020 , 11, 582348	11
188	System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation. 2020 , 332, 109299	1
187	Response to: Correspondence on Hydroxychloroquine, COVID-19 and the role of the rheumatologist by Graef by Lo. 2020 ,	1
186	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. 2020 , 18, 390	21
185	QT interval measurement with portable device during COVID-19 outbreak. 2020 , 30, 100644	2
184	Takotsubo cardiomyopathy in COVID-19: a case report. Haemodynamic and therapeutic considerations. 2020 , 4, 1-6	12
183	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. 2020 , 9,	19
182	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. 2020 , 17, e1003252	55

181	QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment. 2020 , 7, 152		1
180	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2020 , 36, 813		4
179	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. 2020 , 8, 497		10
178	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. 2020 , 148, 25-33		15
177	Ventricular Fibrillation Storm in Coronavirus 2019. 2020 , 135, 177-180		11
176	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. 2020 , 9,		10
175	Arrhythmia in COVID-19. 2020 , 2, 1-6		45
174	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. 2020 , 11, 611275		12
173	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139		41
172	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. 2020 , 20, 538		17
171	Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. 2020 , 10, 21417		6
170	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747		11
169	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?. 2020 , 11, 791		8
168	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. 2020 , 22, 941-956		60
167	Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. <i>Heart Rhythm</i> , 2020 , 17, 1487-1492	6.7	46
166	HRS/EHRA/APHRS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. 2020 , 76, 1363-1374		20
165	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. <i>Heart Rhythm</i> , 2020 , 17, e255-e268	6.7	13
164	A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation. 2020 , 9,		16

163	The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. 2020 , 75, 2381-2383		1
162	The rise and evolution of COVID-19. 2020 , 6, 248-254		2
161	Effects of hydroxychloroquine treatment on QT interval. <i>Heart Rhythm</i> , 2020 , 17, 1930-1935	6.7	27
160	Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas. 2020 , 7, 817-821		6
159	Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. 2020 , 143, 110051		14
158	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666		40
157	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. <i>Heart Rhythm</i> , 2020 , 17, 1480-1486	6.7	18
156	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2021 , 23, 313		17
155	Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course. 2021 , 19, 413-417		9
154	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27		14
153	Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. 2021 , 51, e13428		12
152	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. 2021 , 75, e13896		8
151	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008		14
150	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891		1
149	A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19. 2021 , 21, 159-168		2
148	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. 2021 , 5, 137-150		21
147	Repurposing drugs for the management of COVID-19. 2021 , 31, 295-307		23
146	Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan. 2021 , 32, 100685		4

145	Hydroxychloroquine: Not a Heart Breaker!. 2021 , 73, 770-771	
144	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
143	Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?. 2021 , 102, 389-391	2
142	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. 2021 , 59, 12-23	24
141	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. 2021 , 394, 775-782	10
140	Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. 2021 , 38, 480-488	
139	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. 2021 , 27, 19-27	144
138	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
137	Encyclopedia of Molecular Pharmacology. 2021 , 1-18	
136	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0
135	Potential adverse effects of coronavirus disease 2019 on the cardiovascular system.. 2021 , 6, 30-40	
134	Cardiovascular Health and Disease in the Context of COVID-19. 2021 , 12, 67-79	7
133	Cardiovascular Disease and Coronavirus Disease 2019: Epidemiology, Management, and Prevention. 2021 , 8, 1-8	4
132	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. 2021 , 17, 1538-1546 ¹²	
131	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. 2021 , 180, 356-368	7
130	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	28
129	Association between COVID-19 and Cardiovascular disease. 2021 , 80, 3-5	
128	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1

127	Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients. 2021 , 84, 233-241	17
126	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. 2021 , 15, 510	1
125	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. 2021 , 13,	2
124	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. 2021 , 27, 281-290	8
123	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. 2021 , 75, e14182	2
122	Electrocardiographic manifestations of COVID-19. 2021 , 41, 96-103	32
121	Coronavirus disease 2019 (COVID-19) and QTc prolongation. 2021 , 21, 158	8
120	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. 2021 , 11, 6918	2
119	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. 2021 , 100, e25532	
118	Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. 2021 , 4, e216842	11
117	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706	13
116	Ethical considerations and patient safety concerns for cancelling non-urgent surgeries during the COVID-19 pandemic: a review. 2021 , 15, 19	8
115	Comparison of preprints and final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in interpretation.	2
114	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. 2021 , 19, 1331-1339	2
113	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387	31
112	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. 2021 , 7, 792-802	24
111	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
110	Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues. 2021 , 153, 106-110	2

109	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. 2021 , 153, 72-85	7
108	In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. 2021 , 14, 1155-1165	4
107	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. 2021 , 8,	
106	Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. 2021 , 22, 370	0
105	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. 2021 , 77, 1513-1521	2
104	Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital. 2021 , 79, 100828	
103	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. 2021 , 23, 1124-1133	2
102	Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study. 2021 , 331, 333-339	7
101	Arrhythmias and electrocardiographic findings in Coronavirus disease 2019: A systematic review and meta-analysis. 2021 , 44, 1062-1074	6
100	Predicting QT interval prolongation in patients diagnosed with the 2019 novel coronavirus infection. 2021 , 26, e12853	1
99	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. 2021 , 46, 1308-1311	1
98	Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. 2021 , 183, 227-239	4
97	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. 2021 , 11, 12414	6
96	Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation. 2021 , 22,	6
95	Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. 2021 , 11, e051821	3
94	Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy. 2021 , 100, e26538	2
93	Comparison of ventricular repolarization parameters of Covid-19 patients diagnosed with chest CT and RT-PCR. 2021 , 76, 1013-1018	
92	Comparative Characteristics of Beta-Blockers in Patients with Congenital Long QT Syndrome. 2021 , 17, 492-497	

91	Sudden cardiac death in a young boy with multisystemic inflammatory syndrome in children (MISC). 2021 , 14,	1
90	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. 2021 , 905, 174191	8
89	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. 2021 , 93, 6737-6749	4
88	Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics. 2021 , 12, 684252	3
87	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. 2021 , 4, 1639-1653	0
86	Safety considerations with new antibacterial approaches for chronic bacterial prostatitis. 2021 , 1-12	
85	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study. 2021 , 174, 1395-1403	7
84	Cardiovascular implications of the COVID-19 pandemic. 2021 ,	2
83	Drug-Induced QTc Prolongation: What We Know and Where We Are Going. 2021 ,	1
82	Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study. 2021 , e14882	1
81	Wide complex tachycardia in a patient with COVID-19 treated with chloroquine/azithromycin. 2021 , 2021, omaa124	2
80	Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection. 2021 , 16, 1451-1456	11
79	Comparing of the First Electrocardiographic Variables in Patients with Newly Diagnosed COVID-19 with Healthy Men Volunteer: A Systematic Review and Meta-Analysis. 2021 , 50, 46-57	
78	Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon. 2021 , 11, 106-112	
77	Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases. 2021 , 5, 1-10	0
76	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. 2020 , 15, 1501-1506	18
75	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. 2020 , 88, 106942	5
74	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. 2020 , 28, 1333-1352	11

73	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. 2020 , 13, 913-925	5
72	Concentration-dependent mortality of chloroquine in overdose.	2
71	In Silico design and characterization of multi-epitopes vaccine for SARS-CoV2 from its spike proteins.	4
70	Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon.	2
69	Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments. 2021 , 46, 724-730	8
68	Cardiovascular impact of COVID-19 with a focus on children: A systematic review. 2020 , 8, 5250-5283	33
67	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
66	Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review. 2020 , 11, 593099	4
65	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. 2020 ,	3
64	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020 , 49,	7
63	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. 2020 , 11,	6
62	Concentration-dependent mortality of chloroquine in overdose. 2020 , 9,	17
61	Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. 2021 , 18,	10
60	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. 2021 , 15, 69-76	1
59	Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.	
58	Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.. 2022 , 14, 11-20	1
57	Cardiac arrhythmias associated with COVID-19 infection: state of the art review. 2021 , 19, 881-889	2
56	Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.. 2022 , 14, 95-104	0

55	A Practical Method for QTc Interval Measurement. 2020 , 12, e12122	0
54	QT Interval Prolongation in Patients Treated for COVID-19.	
53	Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic : A review. 2021 , 1	1
52	Coronavirus and Homo Sapiens.	
51	Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19. 2020 , 40, 365-372	0
50	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.	
49	Farmacoterapia aplicada □COVID-19. 58-81	
48	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020 ,	1
47	Evaluation of favipiravir in the treatment of COVID-19 based on the real-world. 2021 ,	4
46	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. 2021 ,	1
45	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. 2021 , 22, 304	0
44	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. 2021 ,	2
43	Encyclopedia of Molecular Pharmacology. 2021 , 560-577	
42	Evaluation of the Prognostic Value of the Admission ECG in COVID-19 Patients: A Meta-Analysis.	
41	Temporal change of ventricular repolarization indices and index of cardioelectrophysiological balance (iCEB) during COVID-19 treatment including hydroxychloroquine at a tertiary referral hospital. 2022 , 5, 7-12	
40	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.. 2022 , 12, 1075	3
39	Repurposing Covid-19 Drug : Current Issues. 2022 , 13, 9-16	
38	QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection.. 2022 , 27, 10742484211069479	

37	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein.. 2022 , 28, 37	
36	Cardiac Arrhythmias in CoVID19. 2022 , 277-290	
35	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. 2022 , 12, e051579	1
34	Cardiovascular care in sub-Saharan Africa during the COVID-19 crisis: lessons from the global experience. 2020 , 31, 113-115	1
33	Antimicrobial agents and torsades de pointes. 2022 , 231-266	
32	Efficacy of treatments tested in COVID-19 patients with cardiovascular disease. A meta-analysis.. 2022 , 2676591211056559	0
31	Can anti-parasitic drugs help control COVID-19?. 2022 ,	1
30	Hydroxychloroquine alone or in combination with azithromycin and corrected QT prolongation in COVID-19 patients: A systematic review. 2021 , 9, 557-567	
29	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	3
28	Drug repurposing strategies and key challenges for COVID-19 management. 2021 , 1-17	4
27	Drug safety of frequently used drugs and substances for self-medication in COVID-19.. 2022 , 13, 20420986221094141	
26	ECG characteristics of COVID -19 patient with arrhythmias: Referral hospitals data from Indonesia.	0
25	Prognostic Value of 12-Leads Electrocardiogram at Emergency Department in Hospitalized Patients with Coronavirus Disease-19.. 2022 , 11,	0
24	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. 2022 , 15, 634	1
23	Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. 2022 , 12,	0
22	Virus, Exosome, and MicroRNA: New Insights into Autophagy. 2022 ,	1
21	The prevalence and course of COVID-19 and the Cardiovascular Diseases.	
20	Early Alterations of QTc in Patients with COVID-19 Treated with Hydroxychloroquine or Chloroquine in Libreville, Gabon. 2022 , 12, 482-490	

- 19 Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks. **2022**, 11,
- 18 Blue Patient and Brown Blood: A Case Series. **2022**, 1, 41-43
- 17 Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study. **2022**, 12, 1612 ○
- 16 Additively manufactured electrodes for the electrochemical detection of hydroxychloroquine. *Talanta*, **2022**, 250, 123727 6.2 ○
- 15 The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.
- 14 Utilization of mechanistic modelling and simulation to analyse fenspiride proarrhythmic potency □ Role of physiological and other non-drug related parameters. ○
- 13 Electrocardiographic Abnormalities in Hospitalized Patients with COVID-19 and the Associations with Clinical Outcome. **2022**, 11, 5248 ○
- 12 Effects of COVID-19 on Arrhythmia. **2022**, 9, 292 ○
- 11 C-L Case Conference: Torsades de Pointes in a Patient with Lifelong Medical Trauma, COVID-19, Remdesivir, Citalopram, Quetiapine and Hemodialysis. **2022**, ○
- 10 Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. **2022**, 27, 92 ○
- 9 Electrochemical sensor based on a ZnO-doped graphitized carbon for the electrocatalytic detection of the antibiotic hydroxychloroquine. Application: tap water and human urine. ○
- 8 The pathological mechanism of the COVID-19 convalescence and its treatment with traditional Chinese medicine. 13, ○
- 7 COVID-19: Inpatient Management. **2023**, 182-232 ○
- 6 Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. **2023**, 152, 1-21 ○
- 5 Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes. ○
- 4 Prospective QTc interval monitoring avoids cardiac toxicity of hydroxychloroquine and azithromycin in critically ill SARS-CoV-2 patients: a cohort study. ○
- 3 SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19. **2023**, 18, e0282151 ○
- 2 Characteristics of Cardiac Abnormalities in Pediatric Patients With Acute COVID-19. **2023**, ○

1 Exploring the Link Between Malaria and COVID-19. **2023**, 311-338

o